Novartis-backed Neurovance bags $6.3M to focus on ADHD

New experimental non-stimulant drug for ADHD appears highly effective and safe
FierceBiotech April 3, 2014 | By Damian Garde
Neurovance said its new drug clocked a statically significant reduction
in ADHD symptoms that was comparable to results with standard
stimulant-based treatments, and the company plans to present its full
safety and efficacy data at the Society for Biological Psychiatry annual
meeting on May 8. CEO McKinney said its triple reuptake inhibitor
modulating norepinephrine, dopamine and serotonin at the same time
has reduced potential for inappropriate nonmedical use.
According to Dr. Harold Levinson, if this drug lives up to
potential it would be an amazing step forward. However, other nonstimulant
experimental drugs have not materialized. And the only
other approved non-stimulant Strattera is significantly less effective
than stimulants.
About Harold Levinson, M.D.
Formerly Clinical Associate Professor of Psychiatry at New York University
Medical Center, Dr. Harold Levinson is currently Director of the Levinson
Medical Center for Learning Disabilities in Long Island, New York. He is a
well-known neuropsychiatrist, clinical researcher and author.

For more information, call 1(800)334-7323 or visit http://www.dyslexiaonline.com.

http://www.fiercebiotech.com/story/novartis-backed-neurovancebags-63m-focus-adhd/2014-04-03

One thought on “Novartis-backed Neurovance bags $6.3M to focus on ADHD

  1. Thank you for forwarding this information on.